Drug Type Fab fragment, Biosimilar |
Synonyms Ranibizumab Biosimilar (Apotex, Inc.), 雷珠单抗生物类似药(Apotex, Inc.) |
Target |
Action inhibitors |
Mechanism VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
Regulation- |


| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Macular Edema | NDA/BLA | Canada | 01 Aug 2025 |






